{"preliminary_commentary":{"by_channel":{"x_thread":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pemigatinib"]],"indication":"metastatic or unresectable urothelial carcinoma with FGF/FGFR alterations","name":"FIGHT-201","nct_id":"NCT02872714","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fight-201-nct02872714. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Pemigatinib in subjects with FGFR3 mutations or fusions.","label":"Cohort A-ID (Intermittent Dose) Pemigatinib","type":"EXPERIMENTAL"},{"description":"Pemigatinib in subjects with FGFR3 mutations or fusions.","label":"Cohort A-CD (Continuous Dose) Pemigatinib","type":"EXPERIMENTAL"},{"description":"Pemigatinib in subjects with other FGF/FGFR alterations.","label":"Cohort B Pemigatinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-02-01","type":"ACTUAL"},"conditions":["UC (Urothelial Cancer)"],"enrollment":{"count":263,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"pemigatinib","otherNames":["INCB054828"],"type":"DRUG"},{"name":"pemigatinib","otherNames":["INCB054828"],"type":"DRUG"}],"last_update":"2025-08-14","lead_sponsor":"Incyte Corporation","official_title":"A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations - (FIGHT-201)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-02-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen","timeFrame":"up to 1138 days"}],"references":[{"citation":"Zhang C, Huang MN, Shan JQ, Hu ZJ, Li ZW, Liu JY. Pemigatinib, a selective FGFR inhibitor overcomes ABCB1-mediated multidrug resistance in cancer cells. Biochem Biophys Res Commun. 2024 Jan 8;691:149314. doi: 10.1016/j.bbrc.2023.149314. Epub 2023 Nov 24.","pmid":"38039831","type":"DERIVED"},{"citation":"Necchi A, Pouessel D, Leibowitz R, Gupta S, Flechon A, Garcia-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot Y. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Ann Oncol. 2024 Feb;35(2):200-210. doi: 10.1016/j.annonc.2023.10.794. Epub 2023 Nov 11.","pmid":"37956738","type":"DERIVED"}],"start_date":{"date":"2017-01-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)","url":"https://clinicaltrials.gov/study/NCT02872714"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fight-201-nct02872714"}